Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
170001700017000
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … Continue reading "Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy"
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Vishal A. Patel (fellowship trained Mohs micrographic surgeon who serves as Director of Cutaneous Oncology at the GW Cancer Center and Director of Dermatologic Surgery at the GW Department of Dermatology) about routine skin cancer checks. Watch as he provides insight on this complex questio … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. George Han (Vice President of the Dermatologic Society of Greater New York, member of the board of directors of the New York State Society of Dermatology and Dermatologic Surgery, and member of the Medical Board of the National Psoriasis Foundation), who offers tips on better directing pa … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Vishal A. Patel (fellowship trained Mohs micrographic surgeon who serves as Director of Cutaneous Oncology at the GW Cancer Center and Director of Dermatologic Surgery at the GW Department of Dermatology) about the pros and cons of gene expression profiling. Watch him describe how this tech … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Adam Friedman (Professor and Chair of Dermatology who serves as Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the GW Department of Dermatology) about why a "mean" approach is most effective when treating warts. Watc … 